Lactobacillus crispatus CTV-05

Your vagina has its own microbiome — a community of microorganisms that, when healthy, is dominated by just a few protective species of Lactobacillus bacteria. One of the most powerful of these is Lactobacillus crispatus, a naturally occurring resident that acts like a protective shield for your vaginal environment. It lowers vaginal pH (making it more acidic), produces hydrogen peroxide and other protective compounds, and essentially crowd-crowds out the troublesome bacteria associated with bacterial vaginosis. CTV-05 is a specific, rigorously studied strain of L. crispatus that was originally isolated from a healthy human vagina and has since been developed into a vaginal live biotherapeutic — meaning it's a living medicine designed to colonize and restore your microbiome from the inside out. Think of it like reseeding a lawn after weeds have taken over: CTV-05 is the premium grass seed, specially chosen to thrive and take hold.

Bacterial vaginosis is one of the most frustrating conditions many women face — not just because of the symptoms like unusual discharge and odor, but because it keeps coming back. Standard antibiotics work, but BV recurs in up to half of women within just a few months of treatment. This is exactly the problem that CTV-05 was designed to solve. In landmark clinical trials, women who used this vaginal biotherapeutic after completing antibiotic treatment were significantly less likely to experience that dreaded BV recurrence compared to those who used a placebo — with effects measurable at both 12 and 24 weeks. Beyond just preventing recurrence, research has shown that restoring a Lactobacillus crispatus-dominant microbiome also helps calm vaginal inflammation. Imagine your vaginal tissues going from an inflamed, agitated state back to calm, balanced, and quietly protected — that's the biological shift this strain is working toward. Researchers have also noted that women who successfully colonized with CTV-05 experienced reductions in markers of tissue irritation and barrier disruption, meaning the vaginal lining itself heals and becomes more resilient. There is also emerging research exploring how restoring this healthy microbiome environment may support broader reproductive health, including connections to preterm birth risk reduction and even HIV susceptibility reduction in high-risk populations.

From a safety perspective, Lactobacillus crispatus CTV-05 has an excellent track record across multiple clinical trials spanning from early-phase safety studies all the way through Phase 2b randomized controlled trials. No serious adverse events have been linked to its use, and the mild side effects that were occasionally reported — such as temporary changes in vaginal discharge or mild local irritation — were no different from those seen in placebo groups. The product has even been studied in pregnant women at high risk of preterm birth, where it was found to be safe and very well-tolerated, with 97% of participants saying they would use it again in future pregnancies. CTV-05 is delivered vaginally as a gel or intravaginal applicator, and the typical protocol used in research involves daily use for the first five days after completing antibiotics, followed by twice-weekly dosing for several more weeks. One important nuance: research suggests that the probiotic works best when BV has been fully cleared by antibiotics first — it's a 'restore and rebuild' tool, not a standalone cure. Sexual activity during the initial colonization period can reduce its effectiveness, so timing matters. This strain is best suited for women who experience recurring BV, those looking to maintain a healthy vaginal microbiome after treatment, or anyone whose healthcare provider has discussed vaginal microbiome restoration as part of their care plan. As always, consulting with a healthcare professional is recommended before starting any new supplement regimen, especially if you are pregnant or managing an active infection.